FindTrial
Sign In

Trastuzumab (Herceptin)

DRUG6 trials

Sponsors

Armando Santoro, MD, Nagoya City University, Alliance for Clinical Trials in Oncology, Institut Curie, Peking University Cancer Hospital & Institute

Conditions

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Breast CancerBreast Cancer, MetastaticEarly Stage Breast CarcinomaHER-2 Positive Breast CancerHER2 + Breast CancerMetastatic Breast Cancer ( HER2 Negative)

Phase 2

Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients
TerminatedNCT00758134
Armando Santoro, MDNON-SMALL CELL LUNG CANCER
Start: 2008-07-31End: 2010-12-31Updated: 2013-05-29
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
RecruitingNCT07193394
Institut CurieMetastatic Breast Cancer ( HER2 Negative), Unresectable Breast Cancer
Start: 2026-01-31End: 2029-06-08Target: 20Updated: 2026-02-23
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Not yet recruitingNCT07527806
Peking University Cancer Hospital & InstituteBreast Cancer
Start: 2026-05-01End: 2029-12-31Target: 156Updated: 2026-04-17
Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)
Not yet recruitingNCT07565324
National Taiwan University HospitalHER-2 Positive Breast Cancer
Start: 2026-04-30End: 2032-12-31Target: 54Updated: 2026-05-04

Phase 3

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
RecruitingNCT06876714
Alliance for Clinical Trials in OncologyAnatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage Breast Carcinoma
Start: 2025-09-17End: 2037-03-13Target: 1524Updated: 2026-05-08

Unknown Phase

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment
Active, not recruitingNCT06663787
Nagoya City UniversityBreast Cancer, Metastatic, HER2 + Breast Cancer
Start: 2024-04-01End: 2026-12-31Target: 50Updated: 2026-05-13